fezolinetant
AssetSmall molecule
Neurokinin 3 (NK3) receptor antagonist that blocks neurokinin B binding in the hypothalamus.
- Stage
- Approved
- Modality
- Small molecule
- Target
- TACR3
- Indications
- 3
- Trials
- 24
- Developers
- 1
Indications
3Hot flashes
Approvedema.europa.eu7 Oct 2026
Menopause
Approvedaccessdata.fda.gov7 Oct 2026
Vasomotor symptoms
Approvedaccessdata.fda.gov7 Oct 2026
- Targets and what it contains1
- Owner and partners1
- Trials24
- Evidence for its targets1
- Competitors9
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026 · 4 sources